Literature DB >> 11554725

Reutilization of immunoblots after chemiluminescent detection.

S H Kaufmann1.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11554725     DOI： 10.1006/abio.2001.5313

Source DB:  PubMed          Journal:  Anal Biochem        ISSN： 0003-2697            Impact factor:   3.365


× No keyword cloud information.
  30 in total

1.  Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.

Authors:  Husheng Ding; Jennifer S McDonald; Seongseok Yun; Paula A Schneider; Kevin L Peterson; Karen S Flatten; David A Loegering; Ann L Oberg; Shaun M Riska; Shengbing Huang; Frank A Sinicrope; Alex A Adjei; Judith E Karp; X Wei Meng; Scott H Kaufmann
Journal:  Haematologica       Date:  2013-08-30       Impact factor: 9.941

2.  Context-dependent antagonism between Akt inhibitors and topoisomerase poisons.

Authors:  Marina Gálvez-Peralta; Karen S Flatten; David A Loegering; Kevin L Peterson; Paula A Schneider; Charles Erlichman; Scott H Kaufmann
Journal:  Mol Pharmacol       Date:  2014-02-25       Impact factor: 4.436

3.  Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.

Authors:  Xue Wei Meng; Michael P Heldebrant; Karen S Flatten; David A Loegering; Haiming Dai; Paula A Schneider; Timothy S Gomez; Kevin L Peterson; Sergey A Trushin; Allan D Hess; B Douglas Smith; Judith E Karp; Daniel D Billadeau; Scott H Kaufmann
Journal:  J Biol Chem       Date:  2009-11-03       Impact factor: 5.157

4.  Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation.

Authors:  Husheng Ding; Jennifer Hackbarth; Paula A Schneider; Kevin L Peterson; X Wei Meng; Haiming Dai; Thomas E Witzig; Scott H Kaufmann
Journal:  Blood       Date:  2011-06-14       Impact factor: 22.113

5.  Exosomes mediate sensory hair cell protection in the inner ear.

Authors:  Andrew M Breglio; Lindsey A May; Melanie Barzik; Nora C Welsh; Shimon P Francis; Tucker Q Costain; Lizhen Wang; D Eric Anderson; Ronald S Petralia; Ya-Xian Wang; Thomas B Friedman; Matthew Ja Wood; Lisa L Cunningham
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

6.  Measurement of BH3-only protein tolerance.

Authors:  Haiming Dai; Husheng Ding; Kevin L Peterson; X Wei Meng; Paula A Schneider; Katherine L B Knorr; Scott H Kaufmann
Journal:  Cell Death Differ       Date:  2017-10-20       Impact factor: 15.828

7.  Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance.

Authors:  Haiming Dai; Husheng Ding; X Wei Meng; Sun-Hee Lee; Paula A Schneider; Scott H Kaufmann
Journal:  Cancer Res       Date:  2013-10-04       Impact factor: 12.701

8.  Cisplatin abrogates the geldanamycin-induced heat shock response.

Authors:  Andrea K McCollum; Kara B Lukasiewicz; Cynthia J Teneyck; Wilma L Lingle; David O Toft; Charles Erlichman
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

9.  Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.

Authors:  Andrea E Wahner Hendrickson; Paul Haluska; Paula A Schneider; David A Loegering; Kevin L Peterson; Ricardo Attar; B Douglas Smith; Charles Erlichman; Marco Gottardis; Judith E Karp; Joan M Carboni; Scott H Kaufmann
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

10.  A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

Authors:  Ivana Gojo; Jan H Beumer; Keith W Pratz; Michael A McDevitt; Maria R Baer; Amanda L Blackford; B Douglas Smith; Steven D Gore; Hetty E Carraway; Margaret M Showel; Mark J Levis; Amy E Dezern; Douglas E Gladstone; Jiuping Jay Ji; Lihua Wang; Robert J Kinders; Marie Pouquet; Ismail Ali-Walbi; Michelle A Rudek; Weijie Poh; James G Herman; Larry M Karnitz; Scott H Kaufmann; Alice Chen; Judith E Karp
Journal:  Clin Cancer Res       Date:  2016-08-08       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.